<DOC>
	<DOCNO>NCT00555412</DOCNO>
	<brief_summary>The objective trial ass safety , tolerability , pharmacokinetics multiple inhaled dos Staccato Loxapine .</brief_summary>
	<brief_title>Staccato Loxapine Multidose PK</brief_title>
	<detailed_description>The purpose present Phase 1 study schizophrenic patient assess safety pharmacokinetics multiple dos Staccato Loxapine give within 24 hour time period . The study conduct schizophrenic patient chronic , stable antipsychotic medication . Patients meet entry criterion randomize one three dose sequence Staccato Loxapine Staccato Placebo . Following administration medication , safety , tolerability pharmacokinetic assessment conduct serial time point .</detailed_description>
	<mesh_term>Loxapine</mesh_term>
	<criteria>Inclusion Criteria include : 1 . Male female subject age 18 65 year , inclusive . 2 . Subjects stable , oral , chronic ( &gt; 2 mo ) antipsychotic medication regimen able tolerate rapid oral dose taper substitution regimen . Exclusion Criteria include : 1 . Subjects currently treat injectable depot neuroleptic within one dose interval must exclude . 2 . Subjects receive loxapine amoxapine within last 30 day must exclude . 3 . Subjects history allergy intolerance dibenzoxazepines ( loxapine amoxapine ) must exclude . 4 . Subjects history movement disorder include Parkinson 's disease history neuroleptic malignant syndrome must exclude . 5 . Subjects history within past year drug alcohol dependence abuse define DSM4 must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>multidose</keyword>
	<keyword>Staccato Loxapine</keyword>
</DOC>